CysLT subtype 1 receptor (CysLT1) Antagonists:アンタゴニストのグローバル市場2015(薬開発、治験動向)

◆英語タイトル:CysLT subtype 1 receptor (CysLT1) Antagonists -Pipeline Insights, 2015
◆商品コード:DIMRMOA5218
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥135,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s,“CysLT subtype 1 receptor (CysLT1) Antagonists-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under CysLT subtype 1 receptor (CysLT1) Antagonists. This report provides information on the therapeutic development based on the CysLT subtype 1 receptor (CysLT1) Antagonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of CysLT subtype 1 receptor (CysLT1) Antagonists
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the CysLT subtype 1 receptor (CysLT1) Antagonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for CysLT subtype 1 receptor (CysLT1) Antagonists and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

【レポートの目次】

• CysLT subtype 1 receptor (CysLT1) Antagonists Overview
• CysLT subtype 1 receptor (CysLT1) Antagonists Disease Associated
• CysLT subtype 1 receptor (CysLT1) Antagonists Pipeline Therapeutics
• CysLT subtype 1 receptor (CysLT1) Antagonists Therapeutics under Development by Companies
• CysLT subtype 1 receptor (CysLT1) Antagonists Late Stage Products (Filed and Phase III)
• Comparative Analysis
• CysLT subtype 1 receptor (CysLT1) Antagonists Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• CysLT subtype 1 receptor (CysLT1) Antagonists Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• CysLT subtype 1 receptor (CysLT1) Antagonists Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• CysLT subtype 1 receptor (CysLT1) Antagonists – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• CysLT subtype 1 receptor (CysLT1) Antagonists – Discontinued Products
• CysLT subtype 1 receptor (CysLT1) Antagonists – Dormant Products
• Companies Involved in Therapeutics Development for CysLT subtype 1 receptor (CysLT1) Antagonists
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for CysLT subtype 1 receptor (CysLT1) Antagonists by Therapy Area, 2015
• Number of Products under Development for CysLT subtype 1 receptor (CysLT1) Antagonists, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Monotherapy Products
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Combination Products
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Route of Administration
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Stage and Route of Administration
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Molecule Type
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Stage and Molecule Type
• CysLT subtype 1 receptor (CysLT1) Antagonists Therapeutics – Discontinued Products
• CysLT subtype 1 receptor (CysLT1) Antagonists Therapeutics – Dormant Products
• Products under Development by Companies, 2015

• Number of Products under Development for CysLT subtype 1 receptor (CysLT1) Antagonists by Therapy Area, 2015
• Number of Products under Development for CysLT subtype 1 receptor (CysLT1) Antagonists, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Monotherapy Products
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Combination Products
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Route of Administration
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Stage and Route of Administration
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Molecule Type
• CysLT subtype 1 receptor (CysLT1) Antagonists Assessment by Stage and Molecule Type

【レポートのキーワード】

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[CysLT subtype 1 receptor (CysLT1) Antagonists:アンタゴニストのグローバル市場2015(薬開発、治験動向)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆